Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ocugen, Inc.NASDAQ: OCGN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 320.42M shares rose 9.7% year over year, in line with the +9.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.7% toward the trailing-twelve-month pace of +9.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
320.42M+2.6% QoQ
Last fiscal yearDec 2025
300.17M+10.8% YoY
LTMMar 2026
307.2M+9.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.7%——
1 year+10.8%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
300.17M USD
Year-over-year change
+10.8%
4-year CAGR
+11.4%

Weighted Avg Shares (Diluted) vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's LTM Mar 2026 weighted avg shares (diluted) of 307.2M shares is the 2nd highest of the 10 companies compared; the peer median is 138.66M shares.
  • Its year-over-year change of +9.9% is the 6th highest of 10, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of +14.5%.
OCGN Competitors Peer median
Weighted Avg Shares (Diluted) for OCGN and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.66M +6.8%+29.9%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026237.13M +18.0%+10.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
FULCFulcrum Therapeutics, Inc.LTM Mar 202666.18M +9.2%+12.1%
OMEROmeros CorporationLTM Mar 202662.97M +8.5%+0.4%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding OCGN) 138.66M+14.7%+14.5%

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.49M6.04M4.06M4.41M
Cost of Revenue00704K1.97M2.39M
Gross Profit02.49M5.33M2.09M2.02M
Gross Margin—100.0%88.3%51.5%45.9%
Research & Development35.11M56.16M39.57M32.13M39.75M
Selling, General & Admin22.92M35.4M31.99M26.69M27.58M
Operating Expenses58.03M91.56M70.86M56.84M64.94M
Depreciation & Amortization229K480K704K1.97M2.39M
EBITDA(58.11M)(86.32M)(62.37M)(52.09M)(60.27M)
EBITDA Margin—-3469.6%-1033.4%-1284.5%-1365.7%
Operating Income(58.03M)(89.07M)(65.53M)(54.76M)(62.92M)
Operating Margin—-3580.0%-1085.7%-1350.4%-1425.7%
Interest Income01.4M2.5M1.3M922K
Interest Expense79K0005.19M
Other Income / Expenses(389K)2.27M2.45M703K(4.93M)
Income Before Tax(58.42M)(86.8M)(63.08M)(54.05M)(67.85M)
Pre-Tax Margin—-3488.9%-1045.0%-1333.0%-1537.4%
Income Tax Expense(52K)0000
Net Income(58.37M)(86.8M)(63.08M)(54.05M)(67.85M)
Net Margin—-3488.9%-1045.0%-1333.0%-1537.4%
EPS (Basic)(0.30)(0.40)(0.26)(0.20)(0.23)
EPS (Diluted)(0.30)(0.40)(0.26)(0.20)(0.23)
Weighted Avg Shares195.01M214.6M244.33M271M300.17M
Weighted Avg Shares (Diluted)195.01M214.6M244.33M271M300.17M

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.